Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"

Published 20/07/2022, 20:50
© Reuters.  Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"
RCOR
-
DYN
-

  • Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price target of $17.
  • "We believe that Avidity and Dyne are an intriguing small-cap story that, while not immune to the selloff of the biotech sector over the past seven months, warrants a fresh look by investors, Chardan analysts wrote.
  • Chardan says Avidity's antibody oligonucleotide conjugate (AOC) design and Dyne's proprietary FORCE design platform leverage well-characterized components.
  • Related: Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew.
  • "The value created by the companies thus far is the well-characterized understanding of how to get all of the components to work together in an optimum fashion," Chardan added.
  • Hence, the key reason Chardan believes that Avidity's AOC and Dyne's FORCE design approach is an enabling technology that can advance small RNA therapeutics to move beyond the liver successfully.
  • Price Action: DYN stock is down 0.93% at $10.35, and RNA shares are up 5.63% at $18.76 during the market session on the last check Wednesday.
Latest Ratings for DYN DateFirmActionFromTo
Oct 2020JP MorganInitiates Coverage OnOverweight
Oct 2020StifelInitiates Coverage OnBuy
Oct 2020JefferiesInitiates Coverage OnBuy
View More Analyst Ratings for DYN

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.